4AW5 | pdb_00004aw5

Complex of the EphB4 kinase domain with an oxindole inhibitor


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.33 Å
  • R-Value Free: 
    0.279 (Depositor), 0.279 (DCC) 
  • R-Value Work: 
    0.190 (Depositor), 0.200 (DCC) 
  • R-Value Observed: 
    0.194 (Depositor) 

Starting Model: other
View more details

wwPDB Validation 3D Report Full Report

Validation slider image for 4AW5

Ligand Structure Quality Assessment 


This is version 1.1 of the entry. See complete history

Literature

The Design, Synthesis, and Biological Evaluation of Potent Receptor Tyrosine Kinase Inhibitors.

Kim, M.H.Tsuhako, A.L.Co, E.W.Aftab, D.T.Bentzien, F.Chen, J.Cheng, W.Engst, S.Goon, L.Klein, R.R.Le, D.T.Mac, M.Parks, J.J.Qian, F.Rodriquez, M.Stout, T.J.Till, J.H.Won, K.A.Wu, X.Michael Yakes, F.Yu, P.Zhang, W.Zhao, Y.Lamb, P.Nuss, J.M.Xu, W.

(2012) Bioorg Med Chem Lett 22: 4979

  • DOI: https://doi.org/10.1016/j.bmcl.2012.06.029
  • Primary Citation Related Structures: 
    4AW5

  • PubMed Abstract: 

    Variously substituted indolin-2-ones were synthesized and evaluated for activity against KDR, Flt-1, FGFR-1 and PDGFR. Extension at the 5-position of the oxindole ring with ethyl piperidine (compound 7i) proved to be the most beneficial for attaining both biochemical and cellular potencies. Further optimization of 7i to balance biochemical and cellular potencies with favorable ADME/ PK properties led to the identification of 8h, a compound with a clean CYP profile, acceptable pharmacokinetic and toxicity profiles, and robust efficacy in multiple xenograft tumor models.


  • Organizational Affiliation
    • Exelixis, 210 E. Grand Avenue, South San Francisco, CA 94080, USA.

Macromolecule Content 

  • Total Structure Weight: 33.39 kDa 
  • Atom Count: 2,191 
  • Modeled Residue Count: 261 
  • Deposited Residue Count: 291 
  • Unique protein chains: 1

Macromolecules

Find similar proteins by:|  3D Structure
Entity ID: 1
MoleculeChains  Sequence LengthOrganismDetailsImage
EPHRIN TYPE-B RECEPTOR 4291Homo sapiensMutation(s): 0 
EC: 2.7.10.1
UniProt & NIH Common Fund Data Resources
Find proteins for P54760 (Homo sapiens)
Explore P54760 
Go to UniProtKB:  P54760
PHAROS:  P54760
GTEx:  ENSG00000196411 
Entity Groups
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupP54760
Sequence Annotations
Expand
Reference Sequence

Small Molecules

Ligands 1 Unique
IDChains Name / Formula / InChI Key2D Diagram3D Interactions
30K

Query on 30K



Download:Ideal Coordinates CCD File
B [auth A](3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(5-methoxy-1H-benzimidazol-2-yl)(phenyl)methylidene]-1,3-dihydro-2H-indol-2-one
C30 H31 N5 O2
LETIJBVXDGOQFG-DQSJHHFOSA-N

Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.33 Å
  • R-Value Free:  0.279 (Depositor), 0.279 (DCC) 
  • R-Value Work:  0.190 (Depositor), 0.200 (DCC) 
  • R-Value Observed: 0.194 (Depositor) 
Space Group: P 1 21 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 46.657α = 90
b = 53.978β = 111.06
c = 63.242γ = 90
Software Package:
Software NamePurpose
REFMACrefinement
MOSFLMdata reduction
SCALAdata scaling
MOLREPphasing

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


Entry History 

Deposition Data

Revision History  (Full details and data files)

  • Version 1.0: 2012-08-01
    Type: Initial release
  • Version 1.1: 2024-05-01
    Changes: Data collection, Database references, Derived calculations, Other, Refinement description